Trastuzumab deruxtecan
Trastuzumab deruxtecan, sold under the brand name Enhertu, is a monoclonal antibody medication used for the treatment of breast cancer or for the treatment of gastric or gastroesophageal adenocarcinoma.

Trastuzumab deruxtecan is an antibody-drug conjugate that includes a human epidermal growth factor receptor 2 (HER2)-directed antibody trastuzumab and a topoisomerase I inhibitor conjugate deruxtecan (a derivative of exatecan). Trastuzumab deruxtecan is a human epidermal growth factor receptor 2 (HER2)-directed antibody and topoisomerase inhibitor conjugate, meaning that the drug targets the changes in HER2 that help the cancer grow, divide and spread, and is linked to a topoisomerise inhibitor, which is a chemical compound that is toxic to cancer cells.

It was approved for medical use in the United States in December 2019, in Japan in March 2020, and in the European Union in January 2021.
Q422248
monoclonal antibody
Concept
Q12140
medication
Concept
Q128581
breast cancer
Concept
Q1069596
antibody-drug conjugate
Concept
Q412616
trastuzumab
Concept
Q281044
topoisomerase I inhibitor
Concept
None
deruxtecan
UNK
Q5419343
exatecan
UNK
Q80109553
Trastuzumab deruxtecan
Concept
Q80109553
Trastuzumab deruxtecan
Concept
Q80109553
Trastuzumab deruxtecan
Concept
2019-12-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
December 2019
DATE
2020-03-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
March 2020
DATE
2021-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
January 2021
DATE
+2^^http://www.w3.org/2001/XMLSchema#decimal
2
NUMBER
+2^^http://www.w3.org/2001/XMLSchema#decimal
2
NUMBER
+2^^http://www.w3.org/2001/XMLSchema#decimal
2
NUMBER
+2^^http://www.w3.org/2001/XMLSchema#decimal
2
NUMBER
+2^^http://www.w3.org/2001/XMLSchema#decimal
2
NUMBER
instance of
instance of
part of